CAD: Low-Dose Colchicine for Secondary Prevention of CAD: JACC Aug 2023

CAD: Low-Dose Colchicine for Secondary Prevention of CAD: JACC Aug 2023

The review article was published in the Journal of the American College of Cardiology in August 2023 and was co-authored by Dr. Kyle Nelson, Dr. Valentin Fuster, and Dr. Paul Ridker. The review found that low-grade systemic inflammation, as determined by hsCRP, is a more powerful determinant of recurrent cardiovascular events, cardiovascular death, and all-cause mortality than low-density lipoprotein cholesterol (LDL-C). The review also found that the recent randomized trials of the interleukin-1 inhibitor canakinumab and of the microtubule polymerization inhibitor low-dose colchicine provide evidence that inflammation inhibition safely lowers cardiovascular event rates among statin-treated patients with a magnitude of effect similar to if not greater than that of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, ezetimibe, and other adjunctive lipid-lowering agents. The review concluded that low-dose colchicine (0.5 mg po qd) is an effective and safe therapy for the secondary prevention of CAD. It is particularly beneficial for patients with high hsCRP levels. Reference Article: https://doi.org/10.1016/j.jacc.2023.05.055

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(35)

REDUCE-AMI Trial: Diminishing Role of Beta-Blockers in ACS with preserved LVEF

REDUCE-AMI Trial: Diminishing Role of Beta-Blockers in ACS with preserved LVEF

1. The REDUCE-AMI trial showed no significant benefit of beta-blockers in reducing all-cause mortality or future myocardial infarction in patients with acute myocardial infarction and preserved left v...

24 Jun 20244min

Improving Left Ventricular Ejection Fraction in Heart Failure Patients: Insights from the HF-OPT Study

Improving Left Ventricular Ejection Fraction in Heart Failure Patients: Insights from the HF-OPT Study

The HF-OPT study investigated the improvement of left ventricular ejection fraction (LVEF) beyond 90 days in patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF). In this...

22 Jun 20245min

AI in Cardiovascular Medicine: JACC Review

AI in Cardiovascular Medicine: JACC Review

Overview: This review discusses the use and future directions of AI in cardiology, focusing on areas like electrocardiography, telemetry and wearables, echocardiography, CMR, nuclear cardiology, CT, e...

21 Jun 20246min

2024 ACC Peripheral Artery Disease (PAD) Guidelines

2024 ACC Peripheral Artery Disease (PAD) Guidelines

Collaborative vascular care is emphasized to address health disparities, gaps in medical therapy, structured exercise, and good foot care along with appropriate revascularization to prevent limb loss....

31 Mai 20246min

2024 ACC/AHA Guidelines on Hypertrophic Cardiomyopathy

2024 ACC/AHA Guidelines on Hypertrophic Cardiomyopathy

2024 HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise Mavacamten: Class 1 recommendation for symptomatic obstructive HCM. Exercise: Now allows for "vigorous" activity; competitive lev...

21 Mai 20249min

DOACs: When direct oral anticoagulants should not be used?

DOACs: When direct oral anticoagulants should not be used?

Key Points: Positive Aspects of DOACs: DOACs are acknowledged for their convenience, efficacy, and safety in conditions like atrial fibrillation (AF) and venous thromboembolism (VTE). The review sup...

29 Jan 20244min

Cath: NPO vs Eating before Heart Cath

Cath: NPO vs Eating before Heart Cath

Background: Traditional practice requires fasting before cardiac catheterization, but there's no evidence to support it. Objective: This study compared a heart-healthy pre-procedure diet with fasting ...

26 Jan 20243min

Stable CAD and Angina: PCI without medical therapy as first treatment (ORBITA-2)

Stable CAD and Angina: PCI without medical therapy as first treatment (ORBITA-2)

Key Points In patients not taking antianginal meds, PCI alleviated some—but not all—symptoms Background: Percutaneous coronary intervention (PCI) is commonly used to alleviate stable angina symptom...

22 Jan 20243min

Populært innen Helse

fastlegen
rss-gukild-johaug
hvordan-har-du-det-mann
psykodrama
lydartikler-fra-aftenposten
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-skravla-gar
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
foreldreradet
hjernesterk
morten-ramm-lar-kakla-ga-til-du-sovner
g-punktet
rss-loping-for-nybegynnere
klimaks
rss-garne-damer
treningsprat
kjed-deg-i-sovn-verdens-kjedeligste-podcast
rss-kunsten-a-leve
stetoskopet-tidsskriftets-podkast